FM
PGNX

Forward Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Forward Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-196,576
Closed -$1.03M – 429
2014
Q4 		$1.03M Sell
196,576
-384,240
-66% -$2.3M 0.06% 164
2014
Q3 		$3.01M Buy
+580,816
New +$2.89M 0.18% 83

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Forward Management's PGNX Position: Q1 2015 in Review

Forward Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2015, closing a stake of 196,576 shares — an estimated $1.03M sold.

Forward Management first reported a position in PGNX in Q3 2014 and held it in 2 quarters. The position peaked at $3.01M in Q3 2014. 107 funds tracked by Wall St. Rank hold PGNX as of Q1 2015.

  • Forward Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Forward Management sold 196,576 Progenics Pharmaceuticals Inc shares in Q1 2015, an estimated $1.03M.
  • Forward Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 2 quarters.
  • Forward Management's Progenics Pharmaceuticals Inc position peaked at $3.01M in Q3 2014.
  • 107 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2015.

Based on Forward Management's 13F filing for Q1 2015, filed 14 May 2015.